Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.10. Enanta Pharmaceuticals had a negative return on equity of 3.54% and a negative net margin of 18.92%. The firm had revenue of $9 million for the quarter, compared to analysts’ expectations of $9.19 million. During the same period last year, the firm earned ($0.09) earnings per share. The company’s revenue for the quarter was down 30.8% compared to the same quarter last year.
Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 1.34% during mid-day trading on Friday, hitting $32.48. The company had a trading volume of 136,775 shares. Enanta Pharmaceuticals has a 1-year low of $20.79 and a 1-year high of $37.31. The stock’s market capitalization is $619.82 million. The stock has a 50 day moving average price of $31.31 and a 200-day moving average price of $31.00.
Several large investors have recently added to or reduced their stakes in ENTA. Point72 Asset Management L.P. bought a new stake in Enanta Pharmaceuticals during the first quarter worth about $1,731,000. Credit Suisse AG increased its stake in Enanta Pharmaceuticals by 33.0% in the first quarter. Credit Suisse AG now owns 46,458 shares of the biotechnology company’s stock worth $1,431,000 after buying an additional 11,516 shares during the period. AQR Capital Management LLC increased its stake in Enanta Pharmaceuticals by 9.0% in the first quarter. AQR Capital Management LLC now owns 124,054 shares of the biotechnology company’s stock worth $3,820,000 after buying an additional 10,260 shares during the period. State Street Corp increased its stake in Enanta Pharmaceuticals by 31.8% in the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock worth $23,063,000 after buying an additional 180,586 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Enanta Pharmaceuticals by 180.8% in the first quarter. Bank of America Corp DE now owns 53,474 shares of the biotechnology company’s stock worth $1,647,000 after buying an additional 34,429 shares during the period. 71.61% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Enanta Pharmaceuticals Inc (ENTA) Posts Earnings Results, Beats Estimates By $0.10 EPS” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/05/20/enanta-pharmaceuticals-inc-enta-posts-quarterly-earnings-results-beats-estimates-by-0-10-eps-updated.html.
Separately, Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 12th.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.